INSM - INSMED Inc

140.98
-1.840   -1.305%

Share volume: 1,590,714
Last Updated: 04-21-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.15%

PREVIOUS CLOSE
CHG
CHG%
$142.82
-1.84
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
9%
Profitability 0%
Dept financing 15%
Liquidity 75%
Performance 0%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-2.42%
1 Month
-2.08%
3 Months
-12.10%
6 Months
-12.11%
1 Year
97.89%
2 Year
484.74%
Key data
Stock price
$140.98
P/E Ratio 
0.00
DAY RANGE
$139.58 - $144.07
EPS 
-$6.42
52 WEEK RANGE
$63.81 - $212.75
52 WEEK CHANGE
$99.12
MARKET CAP 
37.118 B
YIELD 
N/A
SHARES OUTSTANDING 
215.552 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-07-2025
BETA 
1.87
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,784,221
AVERAGE 30 VOLUME 
$2,410,013
Company detail
CEO: William H. Lewis
Region: US
Website: insmed.com
Employees: 740
IPO year: 2000
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1.

Recent news